Comparative analysis of endometrium after using levonorgestrel-releasing intrauterine system and copper intrauterine device

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: To date, the risks of pelvic inflammatory diseases, including chronic endometritis, associated with the use of various intrauterine contraceptives, have remained debatable.

AIM: The aim of this study was to conduct a comparative analysis of the endometrial status in women of reproductive age after the use of copper- or levonorgestrel-releasing intrauterine device.

MATERIALS AND METHODS: Morphological and immunohistochemical studies of endometrial biopsies obtained by aspiration Pipelle biopsy were performed after intrauterine device extraction in 18 patients who used a copper-containing intrauterine device and in 12 women who used the levonorgestrel-releasing intrauterine device Mirena. Monoclonal mouse antibodies to CD20, CD138, and α-smooth muscle actin (DAKO, Denmark) were used. Criteria for inclusion of patients in the study are reproductive age, use of an intrauterine device for five years, absence of complications associated with the intrauterine device during its use. Exclusion criteria are a history of pelvic inflammatory diseases, sexually transmitted infections, habitual miscarriage, two or more intrauterine interventions.

RESULTS: After using a copper-containing intrauterine device, signs of chronic inflammation were found in the endometrium such as cytogenic stroma fibrosis with pronounced infiltration by inflammatory cells, positive expression of CD138 (33.3% of observations), CD20 (88.9% of observations with an average number of 27.4 ± 5.7), α-smooth muscle actin (up to 70% of the cytogenic stroma area), and the presence of lymphatic follicles consisting of B lymphocytes (33.3% of observations). During the use of the levonorgestrel-releasing intrauterine device, decidual transformation of cytogenic stroma cells, as well as secretion and atrophy of the glandular epithelium, were found in the endometrium. CD20-positive cells were detected in five out of 12 cases (41.6% of observations with an average number of 12.8 ± 4.6). Expression of CD138 and α-smooth muscle actin was not detected in any of the cases.

CONCLUSIONS: The use of a copper-containing intrauterine device is associated with a high risk of developing chronic endometritis. The absence of signs of chronic inflammation in the endometrium after the use of a levonorgestrel-releasing intrauterine device is probably due to the protective effect of levonorgestrel on the uterine mucosa. Thus, levonorgestrel-releasing intrauterine devices, in comparison with copper-containing intrauterine devices, have a favorable safety profile relative to the endometrium and can be recommended for women of reproductive age, including those who have not given birth.

Full Text

Restricted Access

About the authors

Victoria A. Pechenikova

North-Western State Medical University named after I.I. Mechnikov

Author for correspondence.
Email: p-vikka@mail.ru
ORCID iD: 0000-0001-5322-708X
SPIN-code: 9603-5645
Scopus Author ID: 408079

MD, Dr. Sci. (Med.), Assistant Professor

Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015

Raisa A. Akopyan

North-Western State Medical University named after I.I. Mechnikov

Email: akopjan.raisa@mail.ru
ORCID iD: 0009-0000-4298-2442
SPIN-code: 9116-5157
Scopus Author ID: 57838083900

MD, Cand. Sci. (Med.)

Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015

Yuliana A. Antipova

North-Western State Medical University named after I.I. Mechnikov

Email: yuliana.antipova2001@mail.ru
ORCID iD: 0009-0002-6466-2348
SPIN-code: 4518-2675
Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015

Maria V. Volokhova

North-Western State Medical University named after I.I. Mechnikov

Email: mreedwyn17@gmail.com
ORCID iD: 0009-0000-5538-6287
SPIN-code: 5825-0640
Russian Federation, 41 Kirochnaya St., Saint Petersburg, 191015

References

  1. Scott JR, Gibbs RS, Karlan BY, et al, editors. Danforth’s obstetrics and gynecology. New York: Lippincott Williams and Wilkins; 2003.
  2. Prilepskaya VN, editor. Guide to contraception. Moscow: MEDpress-inform; 2006. EDN: QLMKOB
  3. Uvarova EV. Hormonal contraception: what is it, what is it like, why and who needs it, how to use it? Effective pharmacotherapy. 2011;(1):14–24. (In Russ.) EDN: SELCCH
  4. Federal State Budgetary Institution National Medical Research Center of Obstetrics, Gynecology and Perinatology named after. Academician V.I. Kulakov Ministry of Health of the Russian Federation, Russian Society of Obstetricians and Gynecologists, Russian Society for Contraception. National medical criteria for the acceptability of contraceptive methods. Adapted document “Medical eligibility criteria for the use of WHO contraceptive methods, 5th edition, 2015”. Sukhikh GT, Prilepskaya VN, editors. Moscow; 2023 [cited 18.08.2023]. (In Russ.) Available from: https://drive.google.com/file/d/1eO4kz5jjSNxJzHvAklVN3CdPwOW8ZH10/view
  5. Bitzer J. Contraceptive compliance — why is contraceptive failure still so frequent? Ther Umsch. 2009;66(2):137–143. doi: 10.1024/0040-5930.66.2.137
  6. ACOG Practice Bulletin N. 121: Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol. 2011;118(1):184–196. doi: 10.1097/AOG.0b013e318227f05e
  7. Hatcer RA, Trussell J, Stewart F, et al. Contraceptive technology. New York: Ardent Media;2007.
  8. Prilepskaya VN, Tarasova MA, Nazarova NM, et al. International project “CHOICE”: a brief overview of the research results. Gynecology. 2010;12(4):26–28. (In Russ.) EDN: NBJVNR
  9. Thompson KM, Speidel JJ, Saporta V, et al. Contraceptive policies affect post-abortion provision of longacting reversible contraception. Contraception. 2011;83(1):41–47. doi: 10.1016/j.contraception.2010.06.008
  10. Manuilova IA. Modern contraceptives. Moscow: Medicine; 1983. (In Russ.)
  11. Berek JS, editor. Novak’s Gynecology. Lippincott Williams and Wilkins; 2002. (In Russ.)
  12. Speroff L, Darney FD. Clinical guidelines for contraception. Moscow: BINOM; 2009. EDN: QLTGOX
  13. French RS, Cowan FM, Mansour D, et al. Levonorgestrel-releasing (20 microgram/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives. BJOG. 2000;107(10):1218–1225. doi: 10.1111/j.1471-0528.2000.tb11610.x
  14. Novikov YuI, Kononova ES. The effectiveness of intrauterine contraceptives, side effects and complications during their use // Obstetrics and Gynecology. 1999;(7):46–48. (In Russ.) EDN: OEYVTH
  15. Petrov YuA. Family and health. Moscow: Medical Book; 2014. (In Russ.) EDN: VRRMTD
  16. Petrov YuA, Radzinsky VE, Kalinina EA, et al. Possibilities of targeted therapy for chronic endometritis taking into account the pathomorphotype. Medical Bulletin of the South of Russia. 2015;(4):71–75. (In Russ.)
  17. Petrov YuA. Chronic endometritis in reproductive age: etiology, pathogenesis, diagnosis, treatment and prevention [dissertation]. Moscow; 2012. (In Russ.) EDN: QFNNXJ
  18. Protasova IN, Tskhai VB, Peryanova OV, et al. Clinical, immunological and microbiological indicators for purulent inflammatory diseases of the uterine appendages that developed during the use of intrauterine contraception. Bulletin of the Novosibirsk State University. Series: biology, clinical medicine. 2007;(1):10–14. EDN: HYHUXN (In Russ.)
  19. Strukova VA. Correction of dysbiosis of the reproductive tract in women after long-term use of intrauterine contraceptives. Bulletin of the Orenburg State University. 2012;(6):22–25. (In Russ.) EDN: PDQVTP
  20. Surico N, Tavassoli K, Porcelli A, et al. Risk of occurrence of pelvic inflammatory disease correlated with the duration of use of an intrauterine device. Minerva Ginecol. 1985;37(3):105–108.
  21. Sufrin CB, Postlethwaite D, Armstrong MA, et al. Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease. Obstet Gynecol. 2012;120(6):1314–1321. doi: 10.1097/aog.0b013e318273364c
  22. Birgisson NE, Zhao Q., Secura GM, et al. Positive testing for neisseria gonorrhoeae and chlamydia trachomatis and the risk of pelvic inflammatory disease in IUD users. J Womens Health. 2015;24(5):354–359. doi: 10.1089/jwh.2015.5190
  23. Gemzell-Danielsson K, Apter D, Hauck B, et al. The effect of age, parity and body mass index on the efficacy, safety, placement and user satisfaction associated with two low-dose levonorgestrel intrauterine contraceptive systems: subgroup analyses of data from a phase III trial. PLoS One. 2015;10(9). doi: 10.1371/journal.pone.0135309
  24. Turok DK, Eisenberg DL, Teal SB, et al. A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement. Am J Obstet Gynecol. 2016;215(5):599.e1–599.e6. doi: 10.1016/j.ajog.2016.05.017
  25. Gemzell-Danielsson K, Apter D, Dermout S, et al. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use. Eur J Obstet Gynecol Reprod Biol. 2017;210:22–28. doi: 10.1016/j.ejogrb.2016.11.022
  26. Feichter GE, Tauber PF, Rosenthal E, Ludwig H. Zur bakteriellen Besiedlung kupferhaltiger Intrauterinpessare. Geburtshilfe Frauenheilkd. 1978;38(11):904–914. (In Germ.)
  27. Alipov VI, Korkhov VV. Contraceptives. Leningrad: Medicine; 1985. (In Russ.)
  28. Arndt IG, Petrov YuA. Clinical aspects of the use of subcutaneous hormonal contraceptives. Tauride medical and biological bulletin. 2016;19(2):15–17. (In Russ.) EDN: WCEXNZV
  29. World Health Organization. Intrauterine devices and their role in family planning. Geneva; 1995. (In Russ.) EDN: WCEXNZ
  30. Apter D, Gemzell-Danielsson K, Hauck B, et al. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertil Steril. 2014;101(6). doi: 10.1016/j.fertnstert.2014.03.004
  31. Sukhikh GT, Shurshalina AV. Chronic endometritis: a guide. Moscow: Geotar-Media; 2013. (In Russ.) EDN: GCLHKW
  32. Ellinidi VN, Feoktistov AA, Kazantsev VA, et al. Prognostic value of two morphological forms of chronic endometritis: polypoid and follicular one. Russian Journal of Human Reproduction. 2020;26(1):55-58. (In Russ.) EDN: BZQOAG doi: 10.17116/repro20202601155

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Endometrium after using the levonorgestrel-releasing intrauterine device Mirena: a, decidualization of the cytogenic stroma; b, combined secretory and atrophic changes in the glandular epithelium. Hematoxylin and eosin staining, zoom ×180

Download (360KB)
Indexing metadata
3. Fig. 2. Endometrium after using a copper-containing intrauterine device. a, fibrosis of the cytogenic stroma of the endometrium; b, necrosis of the cytogenic stroma and epithelium of the endometrial glands. Hematoxylin and eosin staining, zoom ×180

Download (398KB)
Indexing metadata
4. Fig. 3. CD20 expression in the endometrium. a, after using the levonorgestrel-releasing intrauterine device Mirena; b, after using a copper-containing intrauterine device. Immunohistochemical study, zoom ×180

Download (172KB)
Indexing metadata
5. Fig. 4. α-Smooth muscle actin expression in the endometrium. a, after using the levonorgestrel-releasing intrauterine device Mirena; b, after using a copper-containing intrauterine device. Immunohistochemical study, zoom ×180

Download (191KB)
Indexing metadata

Copyright (c) 2024 Eсо-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 66759 от 08.08.2016 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия Эл № 77 - 6389 от 15.07.2002 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies